2017
DOI: 10.1182/blood-2017-04-777987
|View full text |Cite
|
Sign up to set email alerts
|

Immunoassay for human serum erythroferrone

Abstract: Erythroferrone (ERFE) is a glycoprotein hormone secreted by erythroblasts in response to stimulation by erythropoietin (EPO). We previously demonstrated that ERFE messenger RNA expression and serum protein concentration increase in mice subjected to hemorrhage or EPO therapy, that ERFE acts on hepatocytes to suppress hepcidin, and that the resulting decrease in hepcidin augments iron delivery for intensified erythropoiesis. We also showed that ERFE contributes to pathological hepcidin suppression and iron over… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

10
133
4
2

Year Published

2017
2017
2023
2023

Publication Types

Select...
9

Relationship

2
7

Authors

Journals

citations
Cited by 113 publications
(149 citation statements)
references
References 6 publications
10
133
4
2
Order By: Relevance
“…However, the aforementioned study of 59 hemodialysis patients did observe a negative correlation between ERFE and hepcidin 7 . Again, assay differences may have contributed to these discrepant observations.…”
mentioning
confidence: 75%
See 1 more Smart Citation
“…However, the aforementioned study of 59 hemodialysis patients did observe a negative correlation between ERFE and hepcidin 7 . Again, assay differences may have contributed to these discrepant observations.…”
mentioning
confidence: 75%
“…However, the study did observe a small ERFE increase (15%-20%) in a subset of 20 hemodialysis patients that received erythropoiesis stimulating agents (continuous erythropoietin receptor activator (CERA) or darbepoetin alfa) at three days post-administration 7 . It should be noted that the ERFE assay used in this study (MyBioSource, San Diego, CA) has different characteristics than the human assay we developed and was not validated in physiological or pathological conditions that would be expected to have elevated ERFE levels such as blood donors or patients with β -thalassemia.…”
mentioning
confidence: 88%
“…In murine models, a hormone named erythroferrone (ERFE) has been identified as the hepcidin suppressing agent produced by erythroblasts [9,31]. In humans, the ERFE ortologue encoded by the gene FAM132B seems also involved in hepcidin suppression under conditions of increased erythropoiesis [32,33], although in combination with other factors still poorly characterized [23]. Finally, inflammation strongly stimulates hepcidin synthesis through several interleukins (IL), mainly IL-6 [34] and IL-1β [35].…”
Section: Pathophysiological Advances In Iron Metabolismmentioning
confidence: 99%
“…But, a complete recovery was not observed in any patient within the study period. In patients with thalassemia, cellular iron uptake is downregulated through hepcidin after many transfusions . A reduced dietary iron uptake and the physiological iron loss (eg, by exfoliation of intestinal mucosa cells) might therefore still compensate the increasing iron stores, as we are evaluating the iron levels from the start of the transfusion therapy.…”
Section: Discussionmentioning
confidence: 99%